A novel approach to induce early remission in high-risk primary membranous nephropathy
Nephrology Dialysis Transplantation · 2024
DOI: 10.1093/ndt/gfae138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Zinaida Kochoyan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Nephrology, Pavlov University, Saint Petersburg, Russian Federation. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Remission Induction, Immunosuppressive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Dokuchaev Soil Science Institute.
Abstract (Originalsprache)
Background
This prospective single-arm trial with historic controls evaluated the efficacy and safety of treatment based on a combination of rituximab, intravenous cyclophosphamide and corticosteroids (RCP) administered at lower cumulative doses for the induction of early remission in primary membranous nephropathy (PMN).
Methods
We prospectively enrolled 30 high-risk PMN patients with persistent nephrotic syndrome (NS) and elevated antibodies to the phospholipase A2 receptor who underwent RCP therapy. We compared the effectiveness of RCP with that of historic controls who received rituximab-based therapy (RTX, n = 15) or cyclosporine + corticosteroids (CSA, n = 42). The primary outcomes were complete remission (CR) and overall remission (OR) by Month 12 and the time to remission.
Results
In the RCP group, the OR and CR rates by 12 months (97% and 60%) were higher than those in the RTX group (60% and 7%, P ≤ .009) and the CSA group (50% and 24%, P ≤ .003). The median time to OR [2.8 (1.6–3.9) months] was shorter compared with RTX [7.1 (3.4–17.5) months, P = .008] and CSA [7.3 (6.0–13.6) months, P < .001]. In adjusted Cox regression, hazard ratios for OR and CR attainment for RCP versus other treatments were 5.2 (95% CI 2.8–9.6) and 4.8 (95% CI 2.2–10.3), respectively. Propensity score–matched group analyses confirmed these results. One serious adverse event occurred in the RCP group in the follow-up of 56 patient-years.
Conclusions
RCP therapy is considered effective and safe for inducing early remission in high-risk PMN patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute of Nephrology, Pavlov University, Saint Petersburg, Russian Federation.
ORCID-Profile: Zinaida Kochoyan, Vladimir A Dobronravov
Förderung
- Dokuchaev Soil Science Institute
Zitieren
APA
Kochoyan, Z., & Dobronravov, V. A. (2024). A novel approach to induce early remission in high-risk primary membranous nephropathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae138
Vancouver
Kochoyan Z, Dobronravov VA. A novel approach to induce early remission in high-risk primary membranous nephropathy. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfae138
BibTeX
@article{Kochoyan2024,
author = {Kochoyan, Zinaida and Dobronravov, Vladimir A},
title = {A novel approach to induce early remission in high-risk primary membranous nephropathy},
journal = {Nephrology Dialysis Transplantation},
year = {2024},
doi = {10.1093/ndt/gfae138}
}
EUVIMED